KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardant Health (GH) Shares Outstanding (Diluted Average) (2019 - 2025)

Guardant Health's Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $125.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 2.14% year-over-year to $125.4 million; the TTM value through Dec 2025 reached $125.4 million, up 2.14%, while the annual FY2025 figure was $125.4 million, 2.14% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $125.4 million at Guardant Health, up from $124.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $125.4 million in Q4 2025 and bottomed at $101.0 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $108.9 million (2023), against an average of $111.9 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) grew 0.8% in 2023 before it increased 18.55% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $101.3 million in 2021, then grew by 0.85% to $102.2 million in 2022, then rose by 9.6% to $112.0 million in 2023, then grew by 9.61% to $122.7 million in 2024, then rose by 2.14% to $125.4 million in 2025.
  • Per Business Quant, the three most recent readings for GH's Shares Outstanding (Diluted Average) are $125.4 million (Q4 2025), $124.3 million (Q3 2025), and $124.0 million (Q2 2025).